Johannes F.E. Mann

46.5k total citations · 23 hit papers
277 papers, 30.0k citations indexed

About

Johannes F.E. Mann is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Nephrology. According to data from OpenAlex, Johannes F.E. Mann has authored 277 papers receiving a total of 30.0k indexed citations (citations by other indexed papers that have themselves been cited), including 123 papers in Cardiology and Cardiovascular Medicine, 91 papers in Endocrinology, Diabetes and Metabolism and 80 papers in Nephrology. Recurrent topics in Johannes F.E. Mann's work include Blood Pressure and Hypertension Studies (73 papers), Diabetes Treatment and Management (63 papers) and Chronic Kidney Disease and Diabetes (43 papers). Johannes F.E. Mann is often cited by papers focused on Blood Pressure and Hypertension Studies (73 papers), Diabetes Treatment and Management (63 papers) and Chronic Kidney Disease and Diabetes (43 papers). Johannes F.E. Mann collaborates with scholars based in Germany, Canada and United States. Johannes F.E. Mann's co-authors include Salim Yusuf, Eberhard Ritz, John B. Buse, Bernard Zinman, Neil R Poulter, Steven P. Marso, Hiddo J.L. Heerspink, Kirstine Brown‐Frandsen, Ricardo Correa‐Rotter and Ernesto L. Schiffrin and has published in prestigious journals such as Nature, New England Journal of Medicine and The Lancet.

In The Last Decade

Johannes F.E. Mann

264 papers receiving 29.1k citations

Hit Papers

Liraglutide and Cardiovascu... 1996 2026 2006 2016 2016 2020 2005 2013 1996 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
    2016 4.9k citations Steven P. Marso, Gilbert H. Daniels et al. New England Journal of Medicine profile →
  2. Dapagliflozin in Patients with Chronic Kidney Disease
    2020 3.0k citations Hiddo J.L. Heerspink, Bergur V. Stefánsson et al. New England Journal of Medicine profile →
  3. Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing Hemodialysis
    2005 1.8k citations Christoph Wanner, Johannes F.E. Mann et al. New England Journal of Medicine profile →
  4. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
    2013 1.5k citations Ricardo Correa‐Rotter, Hiddo J.L. Heerspink et al. profile →
  5. Effect of the Angiotensin-Converting–Enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency
    1996 1.3k citations G. Janin, Francesco Locatelli et al. New England Journal of Medicine profile →
  6. Chronic Kidney Disease
    2007 1.1k citations Johannes F.E. Mann et al. Circulation profile →
  7. Renal Insufficiency as a Predictor of Cardiovascular Outcomes and the Impact of Ramipril: The HOPE Randomized Trial
    2001 1.1k citations Johannes F.E. Mann, Hertzel C. Gerstein et al. Annals of Internal Medicine profile →
  8. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial
    2008 1.0k citations Johannes F.E. Mann, Roland E. Schmieder et al. profile →
  9. Liraglutide and Renal Outcomes in Type 2 Diabetes
    2017 859 citations Johannes F.E. Mann, Kirstine Brown‐Frandsen et al. New England Journal of Medicine profile →
  10. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease
    2021 657 citations Alfred K. Cheung, Tara I. Chang et al. Kidney International profile →
  11. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
    2024 656 citations Vlado Perkovic, Katherine R. Tuttle et al. New England Journal of Medicine profile →
  12. Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin–Angiotensin System on Proteinuria in Renal Disease
    2008 468 citations Johannes F.E. Mann et al. Annals of Internal Medicine profile →
  13. Intensive Supportive Care plus Immunosuppression in IgA Nephropathy
    2015 457 citations Johannes F.E. Mann et al. New England Journal of Medicine profile →
  14. Urinary Sodium and Potassium Excretion and Risk of Cardiovascular Events
    2011 425 citations Salim Yusuf, Peggy Gao et al. profile →
  15. Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease
    2021 176 citations Alfred K. Cheung, Tara I. Chang et al. Kidney International profile →
  16. Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER
    2021 161 citations George L. Bakris, John B. Buse et al. Circulation profile →
  17. The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease
    2023 147 citations Peter Rossing, Florian M.M. Baeres et al. Nephrology Dialysis Transplantation profile →
  18. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
    2024 102 citations Helen M. Colhoun, John Deanfield et al. profile →
  19. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
    2025 89 citations Darren K. McGuire, Nikolaus Marx et al. New England Journal of Medicine profile →
  20. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials
    2024 80 citations Sunil V. Badve, Matthew M.Y. Lee et al. The Lancet Diabetes & Endocrinology profile →
  21. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial
    2024 74 citations Johannes F.E. Mann, Peter Rossing et al. profile →
  22. Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial
    2024 50 citations Richard E. Pratley, Katherine R. Tuttle et al. Journal of the American College of Cardiology profile →
  23. Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes
    2025 44 citations Rajiv Agarwal, Jennifer B. Green et al. New England Journal of Medicine profile →

Peers

Johannes F.E. Mann
Comparison fields: 5 of 170
  • Endocrinology, Diabetes and Metabolism 13.9k
  • Cardiology and Cardiovascular Medicine 10.5k
  • Nephrology 9.3k
  • Surgery 6.1k
  • Molecular Biology 5.1k
Vlado Perkovic Australia
Hiddo J.L. Heerspink Netherlands
Peter Rossing Denmark
Mark E. Cooper Australia
Luís M. Ruilope Spain
Julia B. Lewis United States
Itamar Raz Israel
Robert D. Toto United States
Hans‐Henrik Parving Denmark
Christoph Wanner Germany
Vlado Perkovic Australia View profile →
Citations per field, relative to Johannes F.E. Mann
Johannes F.E. Mann · 1×
Citations per year, relative to Johannes F.E. Mann
Johannes F.E. Mann · 1×

Countries citing papers authored by Johannes F.E. Mann

Since Specialization
Citations

This map shows the geographic impact of Johannes F.E. Mann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Johannes F.E. Mann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Johannes F.E. Mann more than expected).

Fields of papers citing papers by Johannes F.E. Mann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Johannes F.E. Mann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Johannes F.E. Mann. The network helps show where Johannes F.E. Mann may publish in the future.

Co-authorship network of co-authors of Johannes F.E. Mann

This figure shows the co-authorship network connecting the top 25 collaborators of Johannes F.E. Mann. A scholar is included among the top collaborators of Johannes F.E. Mann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Johannes F.E. Mann. Johannes F.E. Mann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Urinary Albumin-to-Creatinine Ratio in Asia
2025 ·Clinical Journal of the American Society of Nephrology ·Rajiv Agarwal, Jennifer B. Green, Hiddo J.L. Heerspink, Johannes F.E. Mann, Janet B. McGill, Amy K. Mottl, Takeshi Osonoi, (unknown), Peter Rossing, Julio Rosenstock, Muthiah Vaduganathan, Li Li, (unknown), Charlie Scott, (unknown), Satoshi Yamashita, Masaomi Nangaku
0
2
Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials
2025 ·Diabetes Care ·Matthew M.Y. Lee, Naveed Sattar, Rodica Pop‐Busui, John Deanfield, Scott S. Emerson, Silvio E. Inzucchi, Johannes F.E. Mann, Nikolaus Marx, Sharon L. Mulvagh, Neil R Poulter, Sunil V. Badve, Richard E. Pratley, Vlado Perkovic, John B. Buse, Darren K. McGuire, (unknown)
12
3
Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial breakdown →
2024 ·Journal of the American College of Cardiology ·Richard E. Pratley, Katherine R. Tuttle, Peter Rossing, Søren Rasmussen, Vlado Perkovic, Olav Wendelboe Nielsen, Johannes F.E. Mann, Richard J. MacIsaac, Mikhail Kosiborod, Zdravko Kamenov, Thomas Idorn, Marco Bo Hansen, Samy Hadjadj, George L. Bakris, Florian M.M. Baeres, Kenneth W. Mahaffey
50
4
Effectiveness and risk of ARB and ACEi among different ethnic groups in England: A reference trial (ONTARGET) emulation analysis using UK Clinical Practice Research Datalink Aurum-linked data
2024 ·PLoS Medicine ·(unknown), Angel Wong, Anna Schultze, Catherine M. Clase, Clémence Leyrat, Elizabeth Williamson, (unknown), Johannes F.E. Mann, Marianne Cunnington, Koon Teo, Shrikant I. Bangdiwala, Peggy Gao, Kevin Wing, Laurie A. Tomlinson
2
5
Cardiorenal effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers among people underrepresented in trials: analysis of routinely collected data with emulation of a reference trial (ONTARGET)
2024 ·American Journal of Epidemiology ·(unknown), Angel Wong, Anna Schultze, Catherine M. Clase, Clémence Leyrat, Elizabeth Williamson, (unknown), Johannes F.E. Mann, Marianne Cunnington, Koon Teo, Shrikant I. Bangdiwala, Peggy Gao, Laurie A. Tomlinson, Kevin Wing
3
6
Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6
2024 ·Nephrology Dialysis Transplantation ·(unknown), David Z.I. Cherney, (unknown), Johannes F.E. Mann, Søren Rasmussen, Peter Rossing, Katherine R. Tuttle, (unknown), Hiddo J.L. Heerspink
10
7
Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials breakdown →
2024 ·The Lancet Diabetes & Endocrinology ·Sunil V. Badve, (unknown), Matthew M.Y. Lee, Naveed Sattar, Hertzel C. Gerstein, Christian T. Ruff, John J.V. McMurray, Peter Rossing, (unknown), Kenneth W. Mahaffey, Johannes F.E. Mann, Helen M. Colhoun, Katherine R. Tuttle, Richard E. Pratley, Vlado Perkovic
80
8
Triglyceride-glucose index, low-density lipoprotein levels, and cardiovascular outcomes in chronic stable cardiovascular disease: results from the ONTARGET and TRANSCEND trials
2023 ·European Journal of Preventive Cardiology ·Bernhard Haring, Helmut Schumacher, Giuseppe Mancia, Koon Teo, Eva Lonn, Felix Mahfoud, Roland E. Schmieder, Johannes F.E. Mann, Karen Sliwa, Salim Yusuf, Michael Böhm
13
9
Fixed-Dose Combination Therapy for the Prevention of Cardiovascular Diseases in CKD
2023 ·Clinical Journal of the American Society of Nephrology ·Sadaf G Sepanlou, Johannes F.E. Mann, Philip Joseph, Prem Pais, Peggy Gao, Maryam Sharafkhah, Gholamreza Roshandel, Salim Yusuf, Reza Malekzadeh
7
10
Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial
2022 ·Diabetologia ·(unknown), Priya Vart, David Z.I. Cherney, Glenn M. Chertow, Niels Jongs, Anna Maria Langkilde, Johannes F.E. Mann, Ofri Mosenzon, John J.V. McMurray, Peter Rossing, Ricardo Correa‐Rotter, Bergur V. Stefánsson, Robert D. Toto, David C. Wheeler, Hiddo J.L. Heerspink
35
11
Management of Blood Pressure in Patients With Chronic Kidney Disease Not Receiving Dialysis: Synopsis of the 2021 KDIGO Clinical Practice Guideline
2021 ·Annals of Internal Medicine ·Charles Tomson, Alfred K. Cheung, Johannes F.E. Mann, Tara I. Chang, William C. Cushman, Susan L. Furth, Fan Fan Hou, Greg Knoll, Paul Muntner, Roberto Pecoits‐Filho, Sheldon W. Tobe, Lyubov Lytvyn, Jonathan C. Craig, David J. Tunnicliffe, Martin Howell, Marcello Tonelli, Michael Cheung, Amy Earley, Joachim H. Ix, Mark J. Sarnak
36
12
Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial
2020 ·Diabetes Care ·Vlado Perkovic, Robert D. Toto, Mark E. Cooper, Johannes F.E. Mann, Julio Rosenstock, Darren K. McGuire, Steven E. Kahn, Nikolaus Marx, John H. Alexander, Bernard Zinman, Egon Pfarr, Sven Schnaidt, Thomas Meinicke, (unknown), Jyothis T. George, Odd Erik Johansen, Christoph Wanner
42
13
Forgotten Technology in the COVID-19 Pandemic: Filtration Properties of Cloth and Cloth Masks—A Narrative Review
2020 ·Mayo Clinic Proceedings ·Catherine M. Clase, Edouard L. Fu, (unknown), Rupert Beale, (unknown), Myrna Dolovich, Meg Jardine, (unknown), (unknown), Johannes F.E. Mann, Roberto Pecoits‐Filho, Wolfgang C. Winkelmayer­, Juan Jesús Carrero
52
14
Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk
2019 ·European Heart Journal ·Michael Böhm, Helmut Schumacher, Koon Teo, Eva Lonn, Felix Mahfoud, Johannes F.E. Mann, Giuseppe Mancia, Josep Redón, Roland E. Schmieder, Nikolaus Marx, Karen Sliwa, Michael A. Weber, Bryan Williams, Salim Yusuf
42
15
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes breakdown →
2016 ·New England Journal of Medicine ·Steven P. Marso, Gilbert H. Daniels, Kirstine Brown‐Frandsen, Peter Lommer Kristensen, Johannes F.E. Mann, Michael A. Nauck, Steven E. Nissen, Stuart Pocock, Neil R Poulter, Lasse Steen Ravn, William M. Steinberg, Mette Stockner, Bernard Zinman, Richard M. Bergenstal, John B. Buse
4935
16
Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving Telmisartan, Ramipril, or Both
2010 ·Circulation ·Michael Böhm, Magnus Baumhäkel, Koon Teo, Peter Sleight, Jeffrey L. Probstfield, Peggy Gao, Johannes F.E. Mann, Rafael Díaz, Gilles R. Dagenais, Garry Jennings, Lisheng Liu, Petr Janský, Salim Yusuf
132
17
Apolipoprotein A-IV Predicts Progression of Chronic Kidney Disease
2005 ·Journal of the American Society of Nephrology ·Eva Boes, Danilo Fliser, Eberhard Ritz, Paul König, Karl Lhotta, Johannes F.E. Mann, Gerhard A. Müller, Ulrich Neyer, Werner Riegel, Peter Riegler, Florian Kronenberg
68
18
Long-term progression of chronic renal insufficiency in the AIPRI extension study
1997 ·Kidney International ·Francesco Locatelli, (unknown), G Maschio, Johannes F.E. Mann, Claudio Ponticelli, Eberhard Ritz, D. Alberti, M Motolese, G. Janin, P Zucchelli
21
19
Different stereological reaction patterns of the myocardium in hypertrophy induced by exercise and pressure overload
1985 ·Image Analysis & Stereology ·Torsten Mattfeldt, Gerhard Mall, (unknown), (unknown), Heinrich Baust, Johannes F.E. Mann, Christoph Hasslacher, Rüdiger Waldherr
3
20
Cardiac function in experimental uremia.
1983 ·PubMed ·W. Kreußer, Johannes F.E. Mann, M Rambausek, (unknown), Otto Mehls, E. Ritz
8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vlado Perkovic Breakdown of academic impact, for papers by Hiddo J.L. Heerspink Breakdown of academic impact, for papers by Peter Rossing Breakdown of academic impact, for papers by Mark E. Cooper Breakdown of academic impact, for papers by Luís M. Ruilope Breakdown of academic impact, for papers by Julia B. Lewis Breakdown of academic impact, for papers by Itamar Raz Breakdown of academic impact, for papers by Robert D. Toto Breakdown of academic impact, for papers by Hans‐Henrik Parving Breakdown of academic impact, for papers by Christoph Wanner
Rankless by CCL
2026